Kolon Life Science runs a chemical business that makes and sells active pharmaceutical ingredients (APIs) for synthetic drugs such as antibiotics and anti-inflammatory painkillers, along with semiconductor and electronic materials, and it develops biologic new drugs led by Invossa (TG-C), a cell and gene therapy for degenerative arthritis. Revenue reached ₩209.0 billion in 2025, up 29.5% year on year, and the company swung back into the black after losses in 2023-2024, posting operating profit of ₩17.6 billion and net profit of ₩25.0 billion; it followed up with net profit of ₩20.8 billion in the first quarter of 2026. What stands out lately is that while the direction — revenue growth and a return to profit — is clear, a large share of earnings came from one-off gains such as consideration for transferring electronic-materials technology; so the steady profitability of the core API business and the outcome of Invossa's (TG-C) U.S. clinical trials will decide the real scorecard ahead.
At-a-glance assessment financial health · growth · profitability · valuation
- Assets that can be turned to cash within a year fall short of near-term liabilities (current ratio 63.6%).
- Revenue rose 29.5% year over year, and the pace is quickening (3-year trend: rising).
- Net profit swung from a loss a year earlier back into the black (a turnaround).
- Most recent quarter (Q1 2026) revenue was 10.8% higher than a year earlier.
- ROE is 4.3% (controlling-interest basis). It is above the sector average.
- Operating margin is 8.4%.
- The P/E sits above the sector median, reflecting elevated expectations.
Ownership & governance As of 2025-12-31
Largest shareholder Kolon 25.11% (corporate)
Controlling bloc incl. related parties 42.44%
With the controlling bloc holding 42%, the ownership structure is stable.
🔎 In-depth analysis
- The company earns money in two main ways.
- Most of its revenue comes from the chemical business.
- It supplies pharmaceutical makers with APIs — the core raw materials that go into a finished drug — such as antibiotic ingredients like nadifloxacin and levofloxacin and anti-inflammatory painkiller ingredients like zaltoprofen, along with pharmaceutical intermediates, and it adds functional chemical materials such as antibacterial agents and water-treatment agents plus materials used in semiconductor and electronic processes.
- The other pillar is the bio business, which develops a new-drug pipeline including Invossa (TG-C), a cell and gene therapy aimed at degenerative arthritis, and KLS-2031, a treatment for neuropathic pain.
- In short, today's actual revenue and profit are supported by sales of APIs and materials, while the biologic new drugs are closer to future growth candidates that still consume more cash.
- The shares trade at ₩40,600, below the 20-day (₩45,325), 60-day (₩52,113) and 120-day (₩55,175) moving averages.
- This is a weak trend sitting under the medium-term moving averages.
- The stock fell hard recently, down 15.0% over one month and 25.4% over three months.
- Against the 52-week high it sits about 42.7% lower.
- The RSI is 36.2, which has not yet reached the level below 30 usually seen as oversold, but marks a zone where selling pressure dominates.
- Start with valuation.
- The P/E ratio (how many times one year of profit the share price is) is 21.3x.
- However, the denominator of that multiple — 2025 net profit of ₩25.0 billion — contains a large share of the one-off gains explained below, so the multiple on the core business alone is more accurately seen as higher than this.
- The P/B (how many times net assets the share price is) is 0.91x, below even the book value of net assets.
- ROE (how much is earned in a year on shareholders' equity) is still low at 4.3%.
- The operating margin is 8.4%.
- The balance sheet is neutral to somewhat burdened.
- The debt ratio (debt against equity) is 156.6%, and the current ratio (assets that can be turned into cash immediately against debt due within a year) is 63.6%, below 100%.
- That means the capacity to cover near-term maturing debt is not ample.
- Factoring in debt makes the picture a bit heavier.
- Net debt (total borrowings minus cash) is about ₩93.1 billion.
- EV/EBIT (enterprise value divided by operating profit — a debt-adjusted counterpart to the P/E) is a high 37x.
- The FCF yield (actual cash generated against market cap) is -5.0%, meaning that over the past year more cash went out than came in.
- In other words, while accounting net profit is positive, actual cash generation is still negative — a point to view together.
- The direction of revenue growth is clear.
- Revenue reached ₩209.0 billion in 2025, up 29.5% year on year, rising for a third straight year and picking up pace.
- The bottom line reversed dramatically.
- Operating profit turned from losses of ₩24.1 billion in 2023 and ₩22.1 billion in 2024 to a ₩17.6 billion profit in 2025.
- Net profit likewise swung from -₩93.1 billion in 2024 to +₩25.0 billion in 2025.
- In the first quarter of 2026 the company posted revenue of ₩49.7 billion (up 10.8% year on year) and net profit of ₩20.8 billion.
- Still, the nature of the earnings deserves a note.
- In 2025 a large one-off gain recognized as consideration for transferring technology and rights related to a semiconductor material (modified polyphenylene oxide, mPPO) lifted profit substantially.
- Indeed, net profit (₩25.0 billion) exceeding operating profit (₩17.6 billion), and first-quarter net profit (₩20.8 billion) reaching seven times operating profit (₩2.9 billion), both stem from such items arising outside operations.
- As a result, this year's profit outlook varies widely depending on how steady the core API business proves and whether further technology transfers or Invossa-related events recur.
- Because of this one-off character, the company's own official annual profit plan is not disclosed either, so rather than force a figure, only the trend and the assumptions are stated honestly.
- The flow of disclosures centers on governance and routine events.
- At the March 2026 annual general meeting the CEO was changed, and there were board-composition changes such as the appointment of outside directors.
- Around the same time the company borrowed funds from related parties, and in May it made an equity investment in a related party.
- It is a structure of continuing fund and equity transactions among group affiliates.
- On the earnings side, a February disclosure (corrected in March) of a change of 30% or more in revenue or profit-and-loss structure confirmed the 2025 return to profit.
- In May the first-quarter 2026 report was filed, confirming the strong net profit of ₩20.8 billion.
- The key variable that divides the business's own course, per disclosures and IR, is the progress of Invossa's (TG-C) U.S.
- Phase 3 clinical trial.
- In sum, this is a stock whose direction has improved but whose quality of earnings must be examined.
- The strengths are clear.
- Revenue has grown at a double-digit pace for three years, and the company has turned from a long stretch of losses into profit.
- A real, tangible core business in APIs and electronic materials underpins the growth.
- A P/B of 0.91x — a price below even net assets — is also a factor that supports the downside.
- On the other hand, the cautions are just as clear.
- A large share of recent profit came from one-off gains such as consideration for technology transfers, so the profitability of the core business alone once those items are stripped out (operating margin 8.4%, ROE 4.3%) is still not high.
- With a negative FCF yield, actual cash generation is still recovering, and a current ratio of 63.6% means near-term financial flexibility is not ample either.
- All told, the structure is strong when the core API margin rises steadily and further technology transfers or Invossa clinical results are confirmed, and weak when the one-off gains fade leaving only core-business profit, or when clinical uncertainty comes to the fore.
🔎 Valuation vs peers Inconclusive
Compared with mid-sized pharma and bio companies that manufacture APIs and pharmaceutical intermediates while also running a new-drug pipeline — Hanmi Pharmaceutical (a large drugmaker centered on new-drug R&D), Pharma Research (high-margin bio and aesthetic materials) and Daewon Pharmaceutical (a synthetic-drug-focused maker) were used as the peer set.
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Hanmi Pharmaceutical | 30.30x | 4.11x | 13.57% |
| Pharma Research | 19.44x | 4.66x | 23.95% |
| Daewon Pharmaceutical | — | 0.67x | -0.52% |
At first glance a P/E of 21.3x looks lower than Hanmi Pharmaceutical (30x) and similar to Pharma Research (19x). But the denominator of that multiple — 2025 net profit — includes a large one-off gain such as consideration for a semiconductor-materials technology transfer, so the multiple on the core business with that item removed is higher than the surface figure. Conversely, Pharma Research and Hanmi Pharmaceutical have core-business margins (operating margins of 40% and 17% respectively) and ROE (24%, 14%) far above Kolon Life Science's (8.4%, 4.3%). In other words, Kolon Life Science's seemingly low P/E should be read with the one-off nature of its earnings in mind rather than as undervaluation. On the other hand, a P/B of 0.91x sits below net assets, a low level in terms of asset value. Because the quality of earnings and the asset-value metric point in different directions, and the normal profit level of the core business is not yet established, a firm over- or undervalued call is held off.
Price history Close · MA20 · MA60
The latest close is ₩40,600 and the market capitalization is ₩531.5 billion. The price sits below its 20-day moving average (₩45,325) and below its 60-day moving average (₩52,113). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 36.2, a neutral level. The one-month change is -15.0%, the three-month change is -25.4%, and the position relative to the 52-week high is -42.7%. Relative strength versus the KOSDAQ is 76 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 77% of all stocks. Over the past three months it lagged the index by 1.5%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.
Relative performance stock vs index · start = 100
Excess return vs index · 3M -1.54% / 6M +5.92% / 12M +12.06%
Key metrics vs sector median
Valuation
The P/E of 21.29x is above the sector median (15.98x). The P/B of 0.91x is below the sector median (1.37x). That said, this P/E is based on last year's (trailing) results. With recent quarterly earnings up sharply, the trailing P/E can look higher than it really is, so a precise read is best done on this year's expected (forward) earnings.
Enterprise value (EV)
EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.
Intrinsic value (DCF estimate)
DCF (discounted cash flow) estimate — discount rate 11.6%, initial growth 4.0%→terminal 2.0%, 10-yr forecast, earnings-based. A reference range that shifts materially with assumptions.
Profitability & financials
Return on equity (ROE) is 4.3%, above the sector average (3.0%). The operating margin is 8.4%. The debt ratio is 156.6%, so the financial structure is moderate.
Growth FY2025 · annual report (consolidated)
| Item | 2023 | 2024 | 2025 | YoY |
|---|---|---|---|---|
| Revenue | $82.6M | $107.0M | $138.5M | +29.49% ↑ faster |
| Operating profit | -$16.0M | -$14.6M | $11.6M | — |
| Net profit | -$20.4M | -$61.7M | $16.5M | — |
| 5-year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $109.7M | $127.5M | $82.6M | $107.0M | $138.5M |
| Operating profit | $2.6M | $1.1M | -$16.0M | -$14.6M | $11.6M |
| Net profit | -$911,262 | $1.4M | -$20.4M | -$61.7M | $16.5M |
| Revenue CAGR | 4-yr avg 6.01% | ||||
Revenue rose 29.5% year over year (2023 ₩124.6 billion → 2024 ₩161.4 billion → 2025 ₩209.0 billion), and the three-year trend is 'rising'. The pace of growth also quickened from the prior year. Over the 5 years on record, revenue compound annual growth (CAGR) is 6.0%. The two-year revenue CAGR is 29.5%. In the most recent quarter (Q1 2026), revenue was 10.8% higher than the same period a year earlier.
Latest quarterly results Q1 2026 · vs year-ago
Technical indicators
What stands out
- Revenue grew 29.5% year over year, a sign of growth.
Points to watch
- The price is high versus peers, so expectations already appear priced in.
Recent news & events searched · sourced
- 2026-05-15EarningsFirst-quarter 2026 report filed. Revenue of ₩49.7 billion (up 10.8% year on year) and net profit of ₩20.8 billion. Net profit far exceeding operating profit of ₩2.9 billion reflects the impact of non-operating items.Short term: confirmation that the profit trend continues, but a large share of earnings arose outside operations, so the quality of earnings needs checking. Source
- 2026-03-26FilingThe annual general meeting in March confirmed board-composition changes, including a change of CEO and the appointment of outside directors.Medium term: a change of management could bring shifts in business priorities and strategic direction. Source
- 2026-03-26FilingDecision to borrow funds from a related party. Liquidity secured through fund transactions with a group affiliate.Short term: reinforces near-term funding flexibility but reflects a funding structure dependent on affiliates. Source
- 2026-03-05EarningsDisclosure of a change of 30% or more in revenue or profit-and-loss structure (corrected). Confirms the 2025 swing to positive operating and net profit.Medium term: official confirmation of the profit reversal after the large losses of 2023-2024. Source
- 2026-05-18FilingDecision to make an equity investment in a related party. Affiliate equity and capital transaction.Medium term: reflects the linkage structure with the group's bio value chain (production and clinical affiliates). Source
Figure cross-check computed ↔ external
Recent filings
- 2026-05-29Large-business-group status disclosure
- 2026-05-18Disclosure
- 2026-05-15PeriodicQuarterly report
- 2026-03-26Disclosure
- 2026-03-26Disclosure
- 2026-03-26Shareholders' meeting notice
- 2026-03-26Disclosure
- 2026-03-18PeriodicAnnual business report
- 2026-03-18Audit report
- 2026-03-11Shareholders' meeting notice
- 2026-03-05Shareholders' meeting notice
- 2026-03-05EarningsAmended filing
📖 Plain-language glossary — expand if you are new to this
- P/E
- How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
- P/B
- Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
- P/S
- Price relative to a year's revenue — useful for growth companies with thin earnings.
- Net debt / EV
- Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
- EV/EBIT · EV/EBITDA · EV/Sales
- Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
- FCF / FCF yield
- Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
- Intrinsic value (DCF)
- Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
- ROE
- How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
- EPS / BPS
- Earnings per share / net assets (book value) per share.
- Operating / net margin
- Profit left from the core business / final profit after tax and interest, per unit of revenue.
- Debt ratio
- Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
- Current ratio
- Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
- Interest coverage
- How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
- Dividend yield / payout ratio
- The year's dividend as a % of today's price / the share of earnings paid out as dividends.
- Revenue CAGR
- Multi-year growth expressed as a single yearly average (compound annual growth rate).
- RSI (short-term signal)
- Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
- MA20 / MA60 (moving averages)
- The 20- and 60-day average price. Price above them signals a firmer short-term trend.
- vs 52-week high
- How far below the past year's peak the price sits now (%).
All figures are for reference only; how they read varies by sector and over time.
Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.
Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.